Akshay Muralidhar, MD
Critical Care Medicine · Scottsdale, AZNPI 1073856423
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (36.0%), consulting fees and food and beverage — rather than concentrated in one kind of arrangement. 31 manufacturers reported payments, led by Merck at 45.0% of the total. 2025 is the largest year on record at $26,574, more than ten times the $195 reported in 2022. Among critical care medicine clinicians in AZ with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 265 payments — averaging $167.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merck$20K
- Actelion Pharmaceuticals US, Inc.$18K
- Bayer$3K
- United Therapeutics Corporation$1K
- GSK$266
- AstraZeneca$238
- plus $2K from 25 others
Across 164 payments — averaging $5065.24 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Merck$536K
- Janssen Research & Development, LLC$181K
- Sumitomo Pharma America, Inc.$94K
- Novartis$20K
What the payments were for
- Consulting fees$14,09032%
- Speaking & faculty fees$15,92536%
- Travel & lodging$5,38412%
- Food & beverage$8,75620%
- Education$1110%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Merck | 38 | $19,930 |
| Actelion Pharmaceuticals US, Inc. | 91 | $17,532 |
| Bayer | 8 | $2,741 |
| United Therapeutics Corporation | 31 | $1,494 |
| GSK | 13 | $266 |
| AstraZeneca | 11 | $238 |
| Johnson & Johnson(2 entities) | 3 | $227 |
| Amgen(2 entities) | 5 | $194 |
| Insmed, Inc. | 7 | $155 |
| Medtronic | 1 | $153 |
| Boehringer Ingelheim | 6 | $149 |
| Viiv Healthcare Company | 7 | $149 |
| Caris MPI, Inc. | 1 | $140 |
| Sanofi | 5 | $112 |
| Astellas Pharma US Inc | 2 | $109 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $102 |
| Regeneron Healthcare Solutions, Inc. | 4 | $92 |
| Sandoz | 4 | $87 |
| Electromed, Inc. | 7 | $64 |
| Verona Pharma, Inc. | 2 | $63 |
| CMP Pharma, Inc. | 2 | $43 |
| Shionogi Inc | 2 | $41 |
| Grifols USA, LLC | 2 | $41 |
| Genentech USA, Inc. | 1 | $24 |
| Viatris Specialty LLC | 1 | $19 |
| Mylan Specialty L.p. | 1 | $19 |
| Vifor Pharma, Inc. | 1 | $19 |
| Baxter Healthcare | 1 | $17 |
| Napo Pharmaceuticals Inc | 1 | $17 |
| Philips North America LLC | 1 | $15 |
| 3b Medical, Inc. | 1 | $10 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- WINREVAIR$19,093
- UPTRAVI$15,528
- Adempas$2,553
- OPSUMIT$1,633
- AZURE XT DR MRI SURESCAN$153
- MI CANCER SEEK$140
- KRYSTEXXA$125
- OPSYNVI$109
How this compares
$44,265 in reported general payments places this provider in the 95th percentile of 175 critical care medicine providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| UptraviSelexipag | 117 | $2,859,881 |
| OpsumitMacitentan | 213 | $2,726,906 |
| AdempasRiociguat | 81 | $1,134,705 |
| Ambrisentan | 155 | $490,503 |
| OpsynviMacitentan/Tadalafil | 37 | $470,966 |
| OfevNintedanib Esylate | 35 | $453,020 |
| Tyvaso DpiTreprostinil | 12 | $293,976 |
| AdcircaTadalafil | 60 | $272,206 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 329 | $258,590 |
| Tadalafil | 226 | $190,747 |
| JardianceEmpagliflozin | 128 | $182,928 |
| RevatioSildenafil Citrate | 14 | $77,672 |
| EliquisApixaban | 56 | $51,176 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 44 | $24,310 |
| Advair HfaFluticasone Propion/Salmeterol | 43 | $22,464 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Actelion Pharmaceuticals US, Inc.Uptravi, Opsumit, Opsynvi | $17,532 | $6,057,753367 claims |
| BayerAdempas | $2,741 | $1,134,70581 claims |
| Boehringer IngelheimOfev, Jardiance | $149 | $635,948163 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta, Arnuity Ellipta | $266 | $311,345423 claims |
| United Therapeutics CorporationAdcirca | $1,494 | $272,20660 claims |
| AstraZenecaFarxiga, Symbicort, Breztri Aerosphere | $238 | $38,87166 claims |
| Johnson & JohnsonXarelto | $227 | $12,77714 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 175 critical care medicine providers in Arizona.
Other critical care medicine in Scottsdale
- Rodrigo Cartin-CebaScottsdale$18K
- Reena BansalScottsdale$10K
- Kenneth SakataScottsdale$4K
- Heemesh SethScottsdale$4K
- Sandra TillScottsdale$3K
- Aditya GuptaScottsdale$3K
- Pritesh PatelScottsdale$3K
- Benjamin CantrillScottsdale$2K
- Randy WeismanScottsdale$2K
- Harseerat RataulScottsdale$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.